One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
doi : 10.1093/ibd/izae024
Volume 30, Issue 12, December 2024
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation
doi : 10.1093/ibd/izae135
Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years Free
doi : 10.1093/ibd/izad302
Oral vs Intravenous Discharge Antibiotic Regimens in the Management of Intra-abdominal Abscesses in Penetrating Crohn’s Disease Free
doi : 10.1093/ibd/izad299
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study Free
doi : 10.1093/ibd/izad315
Preterm Birth and in Utero Exposure to Corticosteroids Are Associated With Increased Infection Risk in Children of Mothers With IBD Free
doi : 10.1093/ibd/izad316
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study Free
doi : 10.1093/ibd/izae009
Monitoring-Based Model for Personalizing Fecal Incontinence in Patients With Crohn’s Disease: A Multicenter Inception Cohort Study Free
doi : 10.1093/ibd/izae006
Thrombocytosis and Transaminitis in Infants Born to Women With Inflammatory Bowel Disease Is Associated With Exposure to Maternal Inflammation In Utero Free
doi : 10.1093/ibd/izae008
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
doi : 10.1093/ibd/izae004
Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis: Result From a Tertiary Referral Center Free
doi : 10.1093/ibd/izae005
Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study
doi : 10.1093/ibd/izae010
Predictors of Complicated Disease Course in Adults and Children With Crohn’s Disease: A Nationwide Study from the epi-IIRN Free
doi : 10.1093/ibd/izae014
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment
doi : 10.1093/ibd/izae015
Our Life Is a Rollercoaster! A Qualitative Phenomenological Study Exploring the Impact of IBD on Family Members
doi : 10.1093/ibd/izae028
Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn’s Disease and Ulcerative Colitis Compared With Healthy Control Individuals
doi : 10.1093/ibd/izad298
Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients
doi : 10.1093/ibd/izae109
Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?
doi : 10.1093/ibd/izae121
Genetically Predicted Higher Levels of Caffeic Acid Are Protective Against Ulcerative Colitis: A Comprehensive Metabolome Analysis
doi : 10.1093/ibd/izae143
Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study
doi : 10.1093/ibd/izae133
Treatment of Active Crohn’s Disease With Exclusive Enteral Nutrition Diminishes the Immunostimulatory Potential of Fecal Microbial Products
doi : 10.1093/ibd/izae124
AI-luminating Artificial Intelligence in Inflammatory Bowel Diseases: A Narrative Review on the Role of AI in Endoscopy, Histology, and Imaging for IBD Free
doi : 10.1093/ibd/izae030
Inequalities in Healthcare Access, Experience and Outcomes in Adults With Inflammatory Bowel Disease: A Scoping Review
doi : 10.1093/ibd/izae077
Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis
doi : 10.1093/ibd/izae142
Older Adults With Inflammatory Bowel Disease Are at Higher Risk of Developing Antibodies to Infliximab
doi : 10.1093/ibd/izad305
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis
doi : 10.1093/ibd/izae011
Pouch Salvage of Long Rectal Cuff Syndrome: Excision of Retained Rectum and Mesorectum With Conversion to Ileoanal Anastomosis
doi : 10.1093/ibd/izae153
Bowel Damage and Disability in Crohn’s Disease: Is it Really Two Birds with One Stone? Free
doi : 10.1093/ibd/izae050
An Open Letter to the Food and Drug Administration and Pharmaceutical Industry Concerning Drug Approval for Children With Inflammatory Bowel Disease
doi : 10.1093/ibd/izae226
Enhancing the Rigor of Research on Herpes Zoster Risk in Patients with IBD Post-SARS-CoV2: Recommendations for Global and Detailed Analyses
doi : 10.1093/ibd/izae208
Letter: Enhancing the Rigor of Research on Herpes Zoster Risk in IBD Patients Post-SARS-CoV2: Recommendations for Global and Detailed Analyses—Authors’ Reply
doi : 10.1093/ibd/izae223
Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices
doi : 10.1093/ibd/izae207
Response to the Letter to the Editor, “Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices�
doi : 10.1093/ibd/izae228
